Prevalence of spondyloarthritis and its subtypes in southern Sweden

Haglund, Emma; Bremander, Ann; Petersson, Ingemar F; Strömbeck, Britta; Bergman, Stefan; Jacobsson, Lennart; Turkiewicz, Aleksandra; Geborek, Pierre; Englund, Martin

doi:10.1136/ard.2010.141598

Cited by 109 publications

(107 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, Swedish data support a low degree of misclassification for the outcomes used in this study such as acute coronary events, where misclassification has been reported to be less than 5% (28,29). Fourth, not including patients with AS or SpA only seen in primary care may exclude approximately 15% (22) of cases possibly with milder disease. Finally, the many comparisons being undertaken yields a possibility for mass significance, and therefore some of the differences found could be attributed to a matter of coincidence.…”

supporting

confidence: 58%

“…The study population and the frequency of medication use are as expected for patients with AS/SpA attending outpatient specialist clinics (22). Notably, the use of conventional DMARDs and glucocorticoids was rather high.…”

Section: Discussionmentioning

confidence: 73%

“…Third, some misclassification regarding case definition, exposure time, comorbidities, and outcomes of interest could occur. Published data, however, suggest that this is of limited importance, since the misclassification rate based on the case definitions for AS/ SpA is less than 10% (22). Moreover, Swedish data support a low degree of misclassification for the outcomes used in this study such as acute coronary events, where misclassification has been reported to be less than 5% (28,29).…”

mentioning

confidence: 59%

See 2 more Smart Citations

Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population‐Based Cohort Study

Kristensen

Jakobsen

Askling

et al. 2015

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. Safety data regarding the use of etoricoxib and other nonsteroidal antiinflammatory drugs (NSAIDs) in ankylosing spondylitis (AS) and other spondyloarthritis (SpA) patients are rather limited. Our objective was to estimate and compare rates of gastrointestinal, renovascular, and cardiovascular adverse events in patients exposed to etoricoxib, celecoxib, or nonselective NSAIDs or totally unexposed to NSAIDs. Methods. We performed a national register-based cohort study on patients with AS or SpA (n 5 21,872) identified in the Swedish national patient register from 1987-2009. Treatment exposure was assessed time dependently based on the prescription drug register from 2006-2009, adjusting for sociodemographics and comorbidities derived from national population-based registers.Results. Exposure to etoricoxib, celecoxib, and nonselective NSAIDs was 7.6%, 3.9%, and 71.2%, respectively. No major risk differences for serious cardiovascular, gastrointestinal, or renal adverse events were seen among the 3 exposure groups. Patients unexposed to NSAIDs had more baseline comorbidities and an increased relative risk for congestive heart failure events during the study period (2.0, 95% confidence interval [95% CI] 1.3-3.2). The relative risk for atherosclerotic events was nonsignificant when compared to the nonselective NSAID group (1.0, 95% CI 0.7-1.5), while the relative risk for gastrointestinal events was lower for unexposed patients (0.5, 95% CI 0.4-0.7). Conclusion. Overall, serious adverse events related to nonselective NSAIDs, etoricoxib, and celecoxib were similar and in the range of what would be expected in a group of SpA patients. Patients unexposed to NSAIDs had considerably more baseline comorbidities and increased risk for congestive heart failure, reflecting a selection of patients being prescribed NSAIDs in clinical practice.

show abstract

supporting

confidence: 58%

Section: Discussionmentioning

confidence: 73%

mentioning

confidence: 59%

See 1 more Smart Citation

Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population‐Based Cohort Study

Kristensen

Jakobsen

Askling

et al. 2015

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…The true prevalence of PsA in the general population is not fully clear, but is reported to be 0.13-0.25% in the Nordic countries (2)(3)(4)(5). By applying classification criteria for psoriatic arthritis [ClASsification criteria for Psoriatic ARthritis (CASPAR) study] (6), the prevalence of PsA in psoriasis patients was estimated to be 13.8% (1), while other studies report a higher prevalence of 27-30% (7)(8)(9).…”

mentioning

confidence: 99%

Disease activity in and quality of life of patients with psoriatic arthritis mutilans: the Nordic PAM Study

Lindqvist

Guðbjörnsson

Iversen

et al. 2017

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

Objective: To describe the social status and health-related quality of life of patients with psoriatic arthritis mutilans (PAM) in the Nordic countries. Method: Patients with at least one mutilated joint confirmed by radiology were studied. Disease activity involving joints and skin, physician-assessed disease activity, and patient's education and work status were recorded. Data from the 36-item Short Form Health Survey, Health Assessment Questionnaire and Dermatology Life Quality Index questionnaire were gathered and correlated with disease duration, pain, and general well-being (visual analogue scale). The controls were 58 Swedish patients with long-standing psoriatic arthritis sine PAM. Results: Sixty-seven patients were included. Patients with PAM had a protracted disease history (33 ± 14 years) and disease onset at a relatively early age (30 ± 12 years). Overall inflammatory activity at inclusion was mild to moderate. The mean number of mutilated joints was 8.2 and gross deformity was found in 16% of patients. Forty per cent were treated with biological and 32% with conventional synthetic disease-modifying anti-rheumatic drugs. Forty-two per cent had retired early or were on sick leave. Impaired functional capacity with little or no ability to perform self-care or everyday tasks was reported by 21% of the patients. Patients between 45 and 60 years of age reported the most impaired quality of life in comparison to the control group. Conclusion: PAM seriously affects social functioning. Whether early recognition of PAM and new forms of therapy can improve disease outcome and quality of life remains to be studied.

show abstract

“…Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with the skin disorder which affects between 0.3 and 1.9% of adults [1][2][3][4][5] and causes considerable morbidity, mortality and substantially affects patient's functionality, psychology, and quality of life [6,7]. Research has shown that patients with PsA have a high risk of developing major systemic …”

Section: Introductionmentioning

confidence: 99%

A clinically based protein discovery strategy to identify potential biomarkers of response to anti‐TNF‐α treatment of psoriatic arthritis

Collins

Butt

Gibson

et al. 2015

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

Prevalence of spondyloarthritis and its subtypes in southern Sweden

Abstract: In Sweden the prevalence of spondyloarthritis leading to a doctor consultation is not much lower than rheumatoid arthritis. PsA was the most frequent subtype followed by AS and USpA, and the two most frequent subtypes PsA and AS also display some distinct sex patterns.

Cited by 109 publications

References 29 publications

Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population‐Based Cohort Study

Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population‐Based Cohort Study

Disease activity in and quality of life of patients with psoriatic arthritis mutilans: the Nordic PAM Study

A clinically based protein discovery strategy to identify potential biomarkers of response to anti‐TNF‐α treatment of psoriatic arthritis

Contact Info

Product

Resources

About